natgillin/translations-raw huggingface dataset:
The patient should take one 5 mg film-coated tablet per day (white) for 7days.
Bolesnik treba uzimati jednu filmom obloženu tabletu od 5 mg (bijelu) dnevno tijekom 7 dana.
The patient should take one 5 mg film-coated tablet per day for 7 days.
Bolesnik treba uzimati jednu filmom obloženu tabletu od 5 mg dnevno tijekom 7 dana.
The patient should take one 5 mg film-coated tablet per day for 7 days.
Bolesnik treba uzimati jednu filmom obloženu tabletu od 5 mg dnevno, tijekom 7 dana.
The patient should take one and a half 10 mg film-coated tablet (15 mg) per day for 7 days.
Bolesnik treba uzimati jednu i pol filmom obloženu tabletu od 10 mg (15 mg) dnevno tijekom 7 dana.
The patient should take one and a half 10 mg film-coated tablet (15 mg) per day for 7days.
Bolesnik treba uzimati jednu i pol filmom obloženu tabletu od 10 mg (15 mg) dnevno tijekom 7 dana.
The patient should take one and a half 10 mg film-coated tablet (15 mg)per day for 7 days.
Bolesnik treba uzimati jednu i pol filmom obloženu tabletu od 10 mg (15 mg) dnevno tijekom 7 dana.
The patient should take one and a half 10 mg film-coated tablets (15 mg) per day for 7 days.
Bolesnik treba uzimati jednu i pol filmom obloženu tabletu od 10 mg (15 mg) dnevno tijekom 7 dana.
The patient should take three 5 mg film-coated tablets (15 mg) per day for 7 days.
Bolesnik treba uzimati tri filmom obložene tablete od 5 mg (15 mg) dnevno tijekom 7 dana.
The patient should take two 10 mg film-coated tablets (20mg) per day.
Bolesnik treba uzimati dvije filmom obložene tablete od 10 mg (20 mg) dnevno.
The patient should take two 5 mg film-coated tablets (10 mg) per day for 7 days.
Bolesnik treba uzimati dvije filmom obložene tablete od 5 mg (10 mg) dnevno tijekom 7 dana.
The patient should then be instructed to self-perform penile modeling activities at home each day for the 6-week period following the physician penile plaque modeling visit of each treatment cycle, according to the detailed instructions provided in the package leaflet.
Bolesnicima treba dati upute za samostalno svakodnevno izvođenje tehnika modeliranja penisa kod kuće, i to u razdoblju od 6 tjedana nakon posjeta na kojem je liječnik napravio postupak modeliranja plaka penisa u svakom ciklusu liječenja, prema detajnim uputama navedenima u uputi o lijeku.
The patient then undergoes the procedures for radionuclide myocardial perfusion imaging, starting with an injection of a radioactive substance 10 to 20 seconds
Bolesnik se zatim podvrgava postupcima slikovne dijagnostike
The patient will be provided with the Patient Alert Card with each prescription.
Bolesnik će dobiti Karticu za bolesnika s upozorenjima uz svaki liječnički recept.
The patient year adjusted incidence of ONJ was 0.2% during the first year of treatment and 1.7% in the second year.
Incidencija prilagođena prema bolesnik-godini za ONČ iznosila je 0,2% tijekom prve godine liječenja i 1,7% u drugoj godini.
The patient's BSA must be recalculated and the Teysuno dose adjusted accordingly if a patient’s weight increases or decreases by ≥10% from the one used for the previous calculation of BSA and the change is clearly not related to fluid retention.
Ako se tjelesna masa poveća ili smanji za ≥ 10% u odnosu na prethodni izračun BSA, mora se ponovno izračunati površina tijela bolesnika i prema njoj prilagoditi doza lijeka Teysuno, osim ako ta promjena nije jasno posljedica zadržavanja tekućine.
The patient's BSA must be recalculated and the Teysuno dose adjusted accordingly if a patient’s weight increases or decreases by ≥10% from the one used for the previous calculation of BSA and the change is clearly not related to fluid retention.
Ako se tjelesna masa poveća ili smanji za ≥ 10% u odnosu na prethodni izračun BSA, mora se ponovno izračunati površina tijela bolesnika i prema njoj prilagoditi doza lijeka Teysuno, osim ako ta promjena nije jasno posljedica zadržavanje tekućine.
the patient's life-style changes, other circumstances arise that may promote an increased susceptibility to hypo- or hyperglycaemia (see section 4.4).
e promijeni način života bolesnika, nastanu druge okolnosti koje mogu dovesti do povećane podložnosti hipoglikemiji ili hiperglikemiji (vidjeti dio 4.4).
the patient's life-style changes, other circumstances arise that may promote an increased susceptibility to hypo- or hyperglycaemia (see section 4.4).
e promjeni način života bolesnika nastanu druge okolnosti koje mogu dovesti do povećane podložnosti hipoglikemiji ili hiperglikemiji (vidjeti dio 4.4).
the patient's weight changes,
e promijeni tjelesna težina bolesnika,
the patient's weight changes,
e promjeni tjelesna težina bolesnika
The patient-specific pack contains a variable number of casings based on the patient’s body weight.
Pakiranje specifično za bolesnika sadrži različiti broj omota ovisno o tjelesnoj težini bolesnika.
The patient-year adjusted overall incidence of confirmed ONJ was 1.1% during the first year of treatment, 3.7% in the second year and 4.6% per year thereafter.
Sveukupna prilagođena incidencija prema bolesnik-godini za potvrđenu ONČ iznosila je 1,1% tijekom prve godine liječenja, 3,7% u drugoj godini i 4,6% po godini nakon toga.
The Patient/carer and close contacts guide shall contain the following key messages:
Vodič za bolesnika/njegovatelja i osobe u neposrednoj blizini će sadržavati sljedeće ključne poruke:
The Patient/Carer educational material shall contain the following key messages: the risk of hepatotoxicity associated with the use of Jinarc the importance of pregnancy prevention, before and during treatment with Jinarc
Edukacijski materijal za bolesnika/njegovatelja sadržavat će sljedeće ključne poruke: rizik od hepatotoksičnosti povezan s primjenom Jinarca važnost prevencije trudnoće, prije i tijekom liječenja Jinarcom
The patients cannot tell whether they received Lucentis or the sham procedure.
Bolesnici ne znaju jesu li primili Lucentis ili placebo.
The patients chosen for the second study were those with frequent attacks, at least two attacks per month on average.
Bolesnici odabrani za drugo ispitivanje imali su česte napadaje ili u prosjeku barem dva napadaja mjesečno.
The patients continued to receive their standard treatments for SLE during the studies.
Bolesnici su tijekom ispitivanja i dalje primjenjivali standardno liječenje za SLE.
The patients differed significantly in age, body weight and plasma volume.
Pacijenti su se značajno razlikovali po dobi, tjelesnoj težini i volumenu plazme.
The patients enrolled in clinical studies (CT-AMT-010-01, CT-AMT 011-01, CT- AMT 011-02) should be followed up in the LPLD registry.
Bolesnici uključeni u klinička ispitivanja (CT-AMT-010-01, CT-AMT 011- 01, CT-AMT 011-02) moraju biti praćeni u registru LPLD.
The patients had an average of 1 to 4 episodes per day while taking maintenance opioid therapy.
Ispitanici su u prosjeku imali 1 do 4 epizode probojne boli dnevno tijekom terapije održavanja opioidima.
The patients had at least one additional coronary heart disease risk factor, including: previous myocardial infarction or stroke (>6 months prior to enrollment) or documentation of other atherosclerotic cardiovascular disease (overall 51.5 %), type 2 diabetes (36.1 %), high density lipoprotein - cholesterol <35 mg/dl or <0.906 mmol/l (11.6 %), left ventricular hypertrophy diagnosed by electrocardiogram or echocardiography (20.9 %), current cigarette smoking (21.9 %).
Bolesnici su imali najmanje jedan dodatni faktor rizika za koronarnu bolest srca, uključujući prethodni infarkt miokarda ili moždani udar (>6 mjeseci prije uključivanja u ispitivanje) ili dokumentaciju o drugoj aterosklerotskoj kardiovaskularnoj bolesti (ukupno 51,5%), šećernu bolest tipa 2 (36,1%), lipoprotein visoke gustoće - kolesterol <35 mg/dl ili <0,906 mmol/l (11,6%), hipertrofiju lijevog ventrikula dijagnosticiranu elektrokardiogramom ili ehokardiografijom (20,9%), aktivni status pušača (21,9%).
The patients had previously been treated but the treatments had not worked or the disease had come back.
Bolesnici su već bili liječeni, međutim ili te prethodne terapije nisu bile uspješne ili se bolest vratila.
The patients had previously been treated with desmopressin or von Willebrand factor and, in the first part of the study, received Voncento for 12 months.
Bolesnici su prethodno liječeni dezmopresinom ili von Willebrandovim faktorom te su u prvom dijelu ispitivanja primali Voncento tijekom 12 mjeseci.
The patients had to present with unprovoked partial seizures or with generalized tonic-clonic seizures only.
Bolesnici su morali imati spontane djelomične napadaje ili samo generalizirane toničko- kloničke napadaje.
The patients had to present with unprovoked partial seizures or with generalized tonic-clonic seizures only.
Bolesnici su morali imati spontane parcijalne napadaje ili samo generalizirane toničko- kloničke napadaje.
The patients in CT-AMT-010-01 have been followed for up to 5 years (n=6) post therapy administration, those in CT-AMT-011-01 for up to 5 years (n=13), and those in CT-AMT-011-02 for up to 1 year (n=3).
Bolesnici u ispitivanju CT-AMT-010-01 praćeni su do 5 godina (n = 6) nakon primjene terapije, bolesnici u ispitivanju CT- AMT-011-01 do 5 godina (n = 13), a bolesnici u ispitivanju CT-AMT-011-02 do 1 godine (n = 3).
The patients in the study were infected with genotypes 1, 2 or 3 and all received treatment for 12 or 24 weeks.
Bolesnici obuhvaćeni ispitivanjem bili su zaraženi genotipovima 1, 2 ili 3 te su svi primali liječenje tijekom 12 ili 24 tjedana.
The patients in this study (n=452) had locally recurrent, inoperable and/or metastatic soft tissue sarcoma of one of two subtypes – leiomyosarcoma or liposarcoma.
Bolesnici u tom ispitivanju (n = 452) imali su jedan od dva podtipa lokalno rekurentnog, inoperabilnog i/ili metastatskog sarkoma mekog tkiva – leiomiosarkom ili liposarkom.
The patients received Hizentra every week for 28 weeks.
Bolesnici su uzimali lijek Hizentra svakog tjedna u razdoblju od 28 tjedana.
The patients received treatment with Yervoy (3 mg per kg bodyweight), treatment with an experimental medicine called ‘gp100’, or treatment with a combination of Yervoy and gp100.
Bolesnici su zaprimili liječenje lijekom Yervoy (3 mg po kg tjelesne težine), liječenje eksperimentalnim lijekom naziva „gp100” ili kombinirano liječenje lijekom Yervoy i gp100.
The patients studied had an MMSE (Mini-Mental State Examination) score of 10–24.
Mini-Mental State Examination - kratki pregled mentalnog stanja).
The patients studied had an MMSE (Mini-Mental State Examination) score of 10–24.
Mini-Mental State Examination – kratki pregled mentalnog stanja).
The patients studied were receiving antiretroviral therapy containing Viramune 200 mg immediate- release tablets twice daily for at least 6 weeks prior to pharmacokinetic sampling, with a median duration of therapy of 3.4 years.
Ispitivani bolesnici dobivali su antiretrovirusnu terapiju koja je sadržavala Viramune 200 mg tablete s trenutnim oslobađanjem dvaput dnevno u trajanju najmanje od 6 tjedana prije uzimanja uzoraka za farmakokinetičku analizu, a medijan trajanja terapije bio je 3,4 godine.
The patients taking 5 mg Volibris once a day could walk an average of 36 m more after 12 weeks of treatment, while the patients taking placebo could walk 9 m less.
Bolesnici koji su uzimali 5 mg Volibrisa jedanput dnevno mogli su hodati u prosjeku 36 m više nakon 12 tjedana liječenja, dok su bolesnici koji su uzimali placebo mogli hodati 9 m manje.
The patients taking Instanyl were allowed to take a second spray ten minutes after the first dose if there had been insufficient pain relief.
Bolesnicima koji su uzimali lijek Instanyl dozvoljena je druga doza spreja deset minuta nakon prve doze ako ublažavanje boli nije dostatno.
The patients taking Nexavar lived for longer without their disease getting worse (167 days, around five and a half months) than those who took placebo (84 days, around three months).
Bolesnici koji uzimaju Nexavar živjeli su duže bez pogoršanja bolesti (167 dana, otprilike pet i pol mjeseci) od onih koji su uzimali placebo (84 dana, otprilike tri mjeseca).
The patients treated with micafungin in clinical studies represent a critically ill patient population that requires multiple medicinal products including antineoplastic chemotherapy, potent systemic immunosuppressants and broad spectrum antibiotics.
Bolesnici liječeni mikafunginom u kliničkim ispitivanjima predstavljaju populaciju kritično bolesnih bolesnika koje je bilo potrebno liječiti s više lijekova uključujući antineoplastičnu kemoterapiju, jake sistemske imunosupresive i antibiotike širokog spektra.
The patients were enrolled into a single phase I (n = 12) or two phase II (n = 14 / n = 14) safety and efficacy studies, and received multiple doses of clofarabine by intravenous infusion (see section 5.1).
Bolesnici su bili uključeni u jedno ispitivanje sigurnosti i djelotvornosti faze I (n = 12) ili dva ispitivanja sigurnosti i djelotvornosti faze II (n = 14 / n = 14) u kojima su intravenskom infuzijom primali višestruke doze klofarabina (vidjeti dio 5.1).
The patients were given an Ozurdex implant or they received a ‘sham’ treatment where an applicator was pressed against their eye but nothing was actually injected.
Bolesnici su primali implantat Ozurdexa ili su primali „lažnu” terapiju kod koje je aplikator pritisnut na njihovo oko, ali ništa nije injektirano.
The patients were randomized to carbamazepine CR 400 -1200 mg/day or levetiracetam 1000 -3000 mg/day, the duration of the treatment was up to 121 weeks depending on the response.
Bolesnici su randomizirani za dobivanje 400 -1200 mg karbamazepina s kontroliranim otpuštanjem (CR) na dan ili 1000 -3000 mg levetiracetama na dan, liječenje je trajalo do 121 tjedna, ovisno o odgovoru.
The patients were randomized to carbamazepine CR 400 – 1200 mg /day or levetiracetam 1000 - 3000 mg /day, the duration of the treatment was up to 121 weeks depending on the response.
Bolesnici su randomizirani za dobivanje 400 -1200 mg karbamazepina s kontroliranim otpuštanjem (CR) na dan ili 1000 - 3000 mg levetiracetama na dan, liječenje je trajalo do 121 tjedna, ovisno o odgovoru.
The patients were randomized to carbamazepine CR 400 – 1200 mg/day or levetiracetam 1000 - 3000 mg/day, the duration of the treatment was up to 121 weeks depending on the response.
Bolesnici su randomizirani za dobivanje 400 -1200 mg karbamazepina s kontroliranim otpuštanjem (CR) na dan ili 1000 - 3000 mg levetiracetama na dan, liječenje je trajalo do 121 tjedna, ovisno o odgovoru.
The patients were randomized to carbamazepine CR 400 – 1200 mg/day or levetiracetam 1000 - 3000 mg/day, the duration of the treatment was up to 121 weeks depending on the response.
Bolesnici su randomizirani za dobivanje 400 – 1200 mg karbamazepina s kontroliranim otpuštanjem (CR) na dan ili 1000 – 3000 mg levetiracetama na dan, liječenje je trajalo do 121 tjedna, ovisno o odgovoru.
The patients were randomized to carbamazepine CR 400 – 1200 mg/day or levetiracetam 1000 – 3000 mg/day, the duration of the treatment was up to 121 weeks depending on the response.
Bolesnici su randomizirani za dobivanje 400 -1200 mg karbamazepina s kontroliranim otpuštanjem (CR) na dan ili 1000 - 3000 mg levetiracetama na dan, liječenje je trajalo do 121 tjedna, ovisno o odgovoru.
The patients were randomized to carbamazepine CR 400 – 1200 mg/day or levetiracetam 1000 – 3000 mg/day, the duration of the treatment was up to 121 weeks depending on the response.
Bolesnici su randomizirani za dobivanje 400 -1200 mg karbamazepina s kontroliranim otpuštanjem (CR) na dan ili 1000 -3000 mg levetiracetama na dan, liječenje je trajalo do 121 tjedna, ovisno o odgovoru.
The patients were randomized to carbamazepine CR 400 – 1200 mg/day or levetiracetam 1000 – 3000 mg/day, the duration of the treatment was up to 121 weeks depending on the response.
Bolesnici su randomizirani za dobivanje 400 – 1200 mg karbamazepina s kontroliranim otpuštanjem (CR) na dan ili 1000 – 3000 mg levetiracetama na dan, liječenje je trajalo do 121 tjedna, ovisno o odgovoru.
The patients were randomized to carbamazepine CR 400--1,200 mg/day or levetiracetam 1,000--3,000 mg/day, the duration of the treatment was up to 121 weeks depending on the response.
Bolesnici su randomizirani za dobivanje 400 do 1200 mg karbamazepina s kontroliranim otpuštanjem (CR) na dan ili 1000 do 3000 mg levetiracetama na dan, liječenje je trajalo do 121 tjedna, ovisno o odgovoru.
The patients were titrated to their optimal dose of rotigotine in weekly increments of 2 mg/24 h starting at 2 mg/24 h to a maximum dose of 8 mg/24 h over 4 weeks.
Optimalna doza rotigotina postignuta je titracijom doze u tjednim razmacima za 2 mg/24 h, počevši od 2 mg/24 h do najveće doze od 8 mg/ 24 h, kroz 4 tjedna.
The patients were titrated to their optimal dose of rotigotine in weekly increments of 2 mg/24 h starting at 4 mg/24 h to a maximum dose of 16 mg/24 h.
Bolesnici su titrirani do optimalne doze rotigotina povećavanjem doze u tjednim razmacima za 2 mg/24 h, počevši od 4 mg/24 h, do najveće doze od 16 mg/ 24 h.
The patients were titrated to their optimal dose of rotigotine or placebo in weekly increments of 2 mg/24 h starting at 2 mg/24 h to a maximum dose of 16 mg/24 h over 8 weeks, followed by a maintenance period of 4 weeks.
Bolesnici su titrirani do njihove optimalne doze rotigotina ili placeba, u tjednim intervalima za 2 mg/24 h, počevši od 2 mg/24 h do najveće doze od 16 mg/24 h kroz 8 tjedana nakon čega je slijedio period održavanja u trajanu od 4 tjedna.
The patients were titrated to their optimal dose of rotigotine or placebo in weekly increments of 2 mg/24 h starting at 2 mg/24 h to a maximum dose of 6 mg/24 h.
Bolesnici su titrirani do optimalne doze rotigotina ili placeba u tjednim razmacima za 2 mg/24 h, s početnom dozom 2 mg/24 h do najveće doze od 6 mg/24 h.
The patients were titrated to their optimal dose of rotigotine or placebo in weekly increments of 2 mg/24 h starting at 2 mg/24 h to a maximum dose of 6 mg/24 h.
Bolesnici su titrirani do optimalne doze rotigotina ili placeba u tjednim razmacima za 2 mg/24 h, s početnom dozom od 2 mg/24 h do najveće doze od 6 mg/24 h.
The patients were titrated to their optimal doses of rotigotine or placebo in weekly increments of 2 mg/24 h starting at 4 mg/24 h.
Bolesnici su titrirani do optimalne doze povećavanjem doze za 2 mg/24 h u tjednim razmacima, počevši od 4 mg/24 h.
The patients were treated for one to three years and the main measure of effectiveness was based on the proportion of patients who had a stroke or a blood clot blocking blood vessels in other parts of the body each year.
Bolesnike se liječilo jednu do tri godine, a glavno mjerilo djelotvornosti temeljilo se na postotku bolesnika koji su imali moždani udar ili krvne ugruške u krvnim žilama u drugim dijelovima tijela.
The patients were treated until their disease got worse or the side effects of treatment became unmanageable.
Bolesnici su liječeni sve dok se njihova bolest nije pogoršala ili nuspojave terapije nisu postale neupravljive.
The patients will receive an identical titration guide and Patient Leaflet in their titration packs of Uptravi.
Isti takav vodič za titraciju i uputu o lijeku bolesnici će dobiti u svom pakiranju za titraciju doze Uptravija.
The patients’ average HbA1c at baseline ranged from 7.6 to 8.5% and patients were treated for at least 52 weeks.
Prosječna razina HbA1c u bolesnika na početku liječenja bila je u rasponu od 7,6 do 8,5 %, a bolesnici su liječeni najmanje 52 tjedna.
The patients’ bone marrow contained up to 30% abnormal cells.
U koštanoj srži bolesnika bilo je do 30 % abnormalnih stanica.
The patients’ HbA1c levels fell from a baseline of over 7.5% by between 1.22 and 1.64%.
Razina HbA1c u bolesnika pala je s osnovne vrijednosti od preko 7,5 % na 1,22 % do 1,64 %.
The patients’ target date for quitting was set at one week after starting treatment and the patients were followed up for a further 40 weeks after their treatment to see if they started smoking again.
Datum prestanka pušenja za bolesnike određen je tjedan dana nakon početka liječenja, a bolesnici su praćeni do 40 tjedana nakon njihovog liječenja kako bi se vidjelo jesu li ponovno počeli pušiti.
The patient’s ability to concentrate and react may be impaired as a result of hypoglycaemia or hyperglycaemia from glimepiride or, for example, as a result of visual impairment.
Sposobnost bolesnika da se usredotoči i reagira može biti narušena zbog hipoglikemije ili hiperglikemije prouzročene glimepiridom ili, na primjer, zbog poremećaja vida.
The patient’s ability to concentrate and react may be impaired as a result of hypoglycaemia.
Bolesnikova sposobnost koncentracije i reagiranja može biti smanjena kao posljedica hipoglikemije.
The patient’s airway should be maintained.
Potrebno je bolesnikov dišni put održavati prohodnim.
The Patient’s Alert Card should contain the following key elements for patients treated with Enbrel:
Kartica s upozorenjima za bolesnika treba sadržavati sljedeće ključne elemente za bolesnike koji se liječe lijekom Enbrel:
The patient’s blood glucose (sugar) should be regularly tested to find the lowest effective dose.
Razina glukoze (šećera) u krvi bolesnika treba se redovito testirati kako bi se utvrdila najniža djelotvorna doza.
The patient’s blood glucose (sugar) should be tested regularly to find the lowest effective dose.
Potrebno je redovito mjeriti razinu glukoze (šećera) u krvi bolesnika kako bi se otkrila najniža djelotvorna doza.
The patient’s blood glucose should be tested regularly to find the lowest effective dose.
Glukozu u bolesnikovoj krvi treba testirati redovito kako bi se otkrila najniža učinkovita doza.
The patient’s blood levels of white blood cells, platelets and haemoglobin should be checked before treatment, to
Prije početka terapije treba provjeriti koncentracije bijelih krvnih stanica,
The Patient’s Booklet should contain the following key messages:
Knjižica za bolesnike mora sadržavati sljedeće ključne poruke:
The patient’s complete blood cell count must be taken before starting treatment and monitored during treatment.
Prije početka liječenja treba napraviti kompletnu krvnu sliku bolesnika i pratiti je tijekom liječenja.
The patient’s condition should be evaluated continuously.
Stanje bolesnika potrebno je kontinuirano procjenjivati.
The patient’s disease should be confirmed by genetic testing whenever possible.
Kad god je to moguće, bolest treba potvrditi genetskim testiranjem.
The patient’s eye should be disinfected and numbed with an anaesthetic before the implant is injected.
Bolesnikovo oko treba dezinficirati i utrnuti anestetikom prije injektiranja implantata.
The patient’s haemostatic functions should be screened prior to surgery.
Prije kirurškoga zahvata treba provjeriti hemostatske funkcije bolesnika.
The patient’s head should be tilted so that the anterior commissure-posterior commissure (ACPC) plane is at right angles to the bore-axis of the PET scanner with the head positioned in a suitable head support.
Postavite odgovarajući podložak ispod bolesnikove glave i podignite mu bradu tako da prednja i stražnja komisurna linija (ACPC) budu pod pravim kutovima u odnosu na os PET snimača.
The patient’s initiation dose of Bronchitol (400 mg) must be used under the supervision and monitoring of an experienced physician or another health care professional appropriately trained and equipped to perform spirometry, monitor oxygen saturation (SpO2), and manage acute bronchospasm (see sections 4.4 and 4.8) including appropriate use of resuscitation equipment.
Početna doza Bronchitola (400 mg) mora se pacijentu dati pod nadzorom i praćenjem iskusnog liječnika ili drugog zdravstvenog djelatnika koji je prošao odgovarajuću obuku i ima mogućnosti izvođenja spirometrije, praćenja zasićenosti kisikom (SpO2) i postupanja u slučaju akutnog bronhospazma (vidjeti dijelove 4.4 i 4.8) uključujući odgovarajuću primjenu opreme za reanimaciju.